Isovue Readi (iopamidol)

Where it stands

The records show Isovue Readi (iopamidol), from Bracco, as approved in the US. The FDA approval milestone is dated 2026-10-09 and is marked as an official source. The application is NDA220583, and the dosage form is listed as a solution.

The records leave the therapeutic area and the indication blank, so this analysis cannot say what the product is approved to treat or diagnose. The CHMP opinion date is also blank, as expected for a US-only record with no EU procedure shown.

Regulatory pathway and designations

The only designation recorded is "New formulation or manufacturer." The FDA approval entry carries the same label. It places the action in a category of approvals that involve a change in formulation or manufacturer. It does not identify a new active ingredient or a new indication.

The records do not say what changed: the formulation, the manufacturing site, the presentation, or something else. They also do not say which NDA submission route was used, or whether the approval is a supplement or an original application under NDA220583. No expedited-review designations, such as priority review or fast track, appear in the data, and no review timeline or PDUFA date is given.

The CHMP field is empty because there is no EU procedure in the record. Nothing here supports a conclusion about EU status or plans.

Safety and pharmacovigilance

The records contain no safety data. There is no label text, boxed warning, risk management commitment, postmarketing requirement, or adverse event information.

Readers who need to assess safety should consult the approved prescribing information and the FDA approval documents for NDA220583. They should check specifically whether the labeling differs from earlier iopamidol products from the same company. The records do not say whether it does.

What to watch

The first step is to retrieve the approval letter and labeling for NDA220583. These should clarify the nature of the formulation or manufacturer change, the approved indication, and any postmarketing conditions. None of these are in the current records.

Beyond that, the records give no information on launch timing, other regional filings, or further regulatory milestones. Any view on those would be speculation.